Michael Langer, DO
Magnetic Resonance Imaging (MRI) · Elyria, OHNPI 1043280480
Payments from drug & device makers
Across 161 payments — averaging $383.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$44K
- AstraZeneca$11K
- Heartflow, Inc.$797
- Johnson & Johnson$745
- Amgen$697
- Boston Scientific$680
- plus $4K from 22 others
What the payments were for
- Consulting fees$2430%
- Speaking & faculty fees$38,49975%
- Travel & lodging$4,1018%
- Food & beverage$8,27216%
- Education$270%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 47 | $44,315 |
| AstraZeneca | 3 | $10,826 |
| Heartflow, Inc. | 7 | $797 |
| Johnson & Johnson | 14 | $745 |
| Amgen | 7 | $697 |
| Boston Scientific | 13 | $680 |
| Abbott | 6 | $653 |
| Novartis | 11 | $469 |
| Boehringer Ingelheim | 9 | $378 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $353 |
| Impulse Dynamics (USA) Inc. | 2 | $267 |
| Pfizer | 9 | $198 |
| Amarin Pharma, Inc. | 4 | $181 |
| Esperion Therapeutics, Inc. | 3 | $162 |
| Shockwave Medical, Inc | 1 | $154 |
| Abiomed | 1 | $126 |
| Medtronic | 1 | $122 |
| Vifor Pharma, Inc. | 1 | $121 |
| Actelion Pharmaceuticals US, Inc. | 1 | $120 |
| Novo Nordisk | 2 | $113 |
| Sanofi-aventis U.S. LLC | 6 | $95 |
| Cvrx, Inc. | 1 | $48 |
| Lundbeck LLC | 2 | $33 |
| Akcea Therapeutics, Inc. | 2 | $29 |
| Bayer | 1 | $19 |
| CSL Behring | 1 | $18 |
| Siemens Medical Solutions USA, Inc. | 1 | $18 |
| Regeneron Healthcare Solutions, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CAMZYOS$43,603
- FFRct$680
- OPTIMIZER$535
- Watchman$369
- Repatha$368
- XARELTO$342
- AVEIR$243
- JARDIANCE$233
- LEQVIO$224
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$154
- MitraClip$129
- Impella$126
- NEXLIZET$125
- NEXLETOL$125
- Vascepa$125
- ENTRESTO$124
- WATCHMAN Access System$124
- CoreValve Evolut$122
- BRILINTA$122
- Veltassa$121
How this compares
Too few magnetic resonance imaging (mri) providers in Ohioto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 246 | $307,491 |
| CamzyosMavacamten | 26 | $218,754 |
| EntrestoSacubitril/Valsartan | 144 | $160,040 |
| Repatha SureclickEvolocumab | 97 | $108,650 |
| JardianceEmpagliflozin | 42 | $57,711 |
| XareltoRivaroxaban | 43 | $56,980 |
| VascepaIcosapent Ethyl | 66 | $52,940 |
| Icosapent Ethyl | 64 | $31,507 |
| FarxigaDapagliflozin Propanediol | 23 | $20,487 |
| Atorvastatin Calcium | 1,003 | $12,391 |
| Metoprolol Succinate | 584 | $8,641 |
| Rosuvastatin Calcium | 436 | $5,840 |
| Ranolazine ErRanolazine | 45 | $5,824 |
| Losartan Potassium | 632 | $5,786 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 324 | $4,312 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $198 | $307,491246 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $44,315 | $218,75426 claims |
| NovartisEntresto | $469 | $160,040144 claims |
| Boehringer IngelheimJardiance | $378 | $57,71142 claims |
| Johnson & JohnsonXarelto | $745 | $56,98043 claims |
| AstraZenecaFarxiga | $10,826 | $20,48723 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few magnetic resonance imaging (mri) providers in Ohioon file to place this against a meaningful peer group, so we don't.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.